ATE537830T1 - Nicotinamid derivate und ihre verwendung als therapeutika - Google Patents

Nicotinamid derivate und ihre verwendung als therapeutika

Info

Publication number
ATE537830T1
ATE537830T1 AT04756752T AT04756752T ATE537830T1 AT E537830 T1 ATE537830 T1 AT E537830T1 AT 04756752 T AT04756752 T AT 04756752T AT 04756752 T AT04756752 T AT 04756752T AT E537830 T1 ATE537830 T1 AT E537830T1
Authority
AT
Austria
Prior art keywords
therapeutics
nicotinamide derivatives
mammal
formula
disclosed
Prior art date
Application number
AT04756752T
Other languages
English (en)
Inventor
Jian-Min Fu
Vishnumurthy Kodumuru
Shaoyi Sun
Michael Winther
Richard Fine
Daniel Harvey
Boris Klebansky
Mark Gray-Keller
Heinz Gschwend
Wenbao Li
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE537830T1 publication Critical patent/ATE537830T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04756752T 2004-07-06 2004-07-06 Nicotinamid derivate und ihre verwendung als therapeutika ATE537830T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/021792 WO2006014168A1 (en) 2004-07-06 2004-07-06 Nicotinamide derivatives and their use as therapeutic agents

Publications (1)

Publication Number Publication Date
ATE537830T1 true ATE537830T1 (de) 2012-01-15

Family

ID=34958141

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04756752T ATE537830T1 (de) 2004-07-06 2004-07-06 Nicotinamid derivate und ihre verwendung als therapeutika

Country Status (10)

Country Link
EP (1) EP1763350B1 (de)
JP (1) JP2008505891A (de)
CN (1) CN1997371A (de)
AT (1) ATE537830T1 (de)
AU (1) AU2004321997A1 (de)
BR (1) BRPI0418939A (de)
CA (1) CA2573198A1 (de)
ES (1) ES2380020T3 (de)
MX (1) MX2007000028A (de)
WO (1) WO2006014168A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517884B2 (en) 1998-03-30 2009-04-14 Kalypsys Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
JP5149009B2 (ja) 2004-09-20 2013-02-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体
AU2005286793A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
EP1807085B1 (de) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterozyklische Derivate und ihre Verwendung als Stearoyl-Coa-Desaturase-Inhibitoren
CA2580857A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CN101084207A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
WO2006034279A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
CN101084212A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
DK1805158T3 (en) 2004-10-29 2018-08-06 Kalypsys Inc SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR
WO2007044085A2 (en) * 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Heteroaryl compounds and their uses as therapeutic agents
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
JP5322650B2 (ja) 2005-10-25 2013-10-23 カリプシス・インコーポレーテッド Ｐｐａｒ調節剤の塩および代謝障害の治療方法
PT2029572E (pt) 2006-06-05 2011-02-09 Novartis Ag Compostos orgânicos
BRPI0719122A2 (pt) 2006-08-24 2013-12-10 Novartis Ag Compostos orgânicos
US20080176861A1 (en) 2007-01-23 2008-07-24 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
US7842696B2 (en) 2007-06-21 2010-11-30 Forest Laboratories Holdings Limited Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
WO2009019149A1 (en) * 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as taar1 ligands
BRPI0815591B8 (pt) 2007-08-22 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, e, uso de um composto.
KR20100052482A (ko) * 2007-08-23 2010-05-19 사노피-아벤티스 아졸로아린 유도체, 이의 제조 방법, 이들 화합물을 함유하는 약제 및 이의 용도
CN101597278B (zh) 2008-06-04 2013-04-17 中国中化股份有限公司 酰胺类化合物及其制备与应用
ES2545864T3 (es) 2009-02-17 2015-09-16 Merck Canada Inc. Nuevos compuestos espiránicos útiles como inhibidores de la estearoil-coenzima A delta-9 desaturasa
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
EP2459568A4 (de) 2009-07-28 2013-02-27 Merck Frosst Canada Ltd Neue spiroverbindungen als hemmer der stearoyl-coenzym-a-delta-9-desaturase
EP2475367A1 (de) 2009-09-10 2012-07-18 Centre National De La Recherche Scientifique Neuartige stearoyl-coa-desaturase-1-hemmer und ihre verwendung
BR112012020782A2 (pt) 2010-02-18 2016-05-03 Astrazeneca Ab composto, e, processo para preparar um composto
BR112012030184A2 (pt) * 2010-05-27 2015-12-29 Bayer Cropscience Ag derivados de ácido piridinilcarboxílico como fungicidas
KR101271538B1 (ko) 2011-06-24 2013-06-05 (주)이뮤노텍 유기산, ｌ―카르니틴, ｌ―아르기닌 및 니코틴아미드를 유효성분으로 포함하는 비만의 예방 및 개선용 조성물
WO2013056148A2 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
RU2014149559A (ru) 2012-05-22 2016-06-27 Ийсум Рисёч Девелопмент Кампани Оф Зэ Хибру Юниверсити Оф Иерусалим Лтд. Селективные ингибиторы недифференцированных клеток
CN110099898B (zh) 2016-10-24 2023-07-25 优曼尼蒂治疗公司 化合物及其用途
CA3049010A1 (en) 2017-01-06 2018-07-12 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
BR112020019191A2 (pt) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
KR20220007845A (ko) 2019-01-24 2022-01-19 유마니티 테라퓨틱스, 인크. 화합물 및 이의 용도
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143906A0 (en) * 1998-12-24 2002-04-21 Aventis Pharmaceuticals Produs Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds as factor xa inhibitors
EP1156045A4 (de) * 1999-01-28 2002-04-17 Nippon Shinyaku Co Ltd Amid-derivate und drogen-zusammensetzungen
DK1035115T3 (da) * 1999-02-24 2005-01-24 Hoffmann La Roche 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister
US6677452B1 (en) * 1999-09-30 2004-01-13 Lion Bioscience Ag Pyridine carboxamide or sulfonamide derivatives and combinatorial libraries thereof
EP1243268A4 (de) * 1999-12-14 2003-05-21 Nippon Shinyaku Co Ltd Medizinische zusammenstellung
US6987001B2 (en) * 2000-02-24 2006-01-17 Xenon Pharmaceuticals Inc. Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
DE60130771T2 (de) * 2000-07-27 2008-07-17 Eli Lilly And Co., Indianapolis Substituierte heterocyclische amide
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
JP4186518B2 (ja) * 2001-06-15 2008-11-26 アステラス製薬株式会社 フェニルピリジン誘導体
DE60230266D1 (de) * 2001-06-15 2009-01-22 Astellas Pharma Inc Phenylpyridincarbonyl piperazinderivate
WO2003037862A1 (en) * 2001-10-30 2003-05-08 Nippon Shinyaku Co., Ltd. Amide derivatives and drugs
US6620811B2 (en) * 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
US7449457B2 (en) * 2001-12-07 2008-11-11 Eli Lilly And Company Substituted heterocyclic carboxamides with antithrombotic activity
ES2416304T3 (es) * 2002-01-18 2013-07-31 Astellas Pharma Inc. Derivado de 2-acilaminotiazol o sal del mismo
ATE395343T1 (de) * 2002-03-13 2008-05-15 Janssen Pharmaceutica Nv Sulfonylderivate als histone-deacetylase- inhibitoren
CA2493584A1 (en) * 2002-07-25 2004-02-05 Wisconsin Alumni Research Foundation Inhibition of stearoyl-coa desaturase 1 (scd1) increases insulin sensitivity and treats diabetes

Also Published As

Publication number Publication date
JP2008505891A (ja) 2008-02-28
AU2004321997A1 (en) 2006-02-09
EP1763350A1 (de) 2007-03-21
BRPI0418939A (pt) 2008-04-08
MX2007000028A (es) 2007-07-20
EP1763350B1 (de) 2011-12-21
CA2573198A1 (en) 2006-02-09
ES2380020T3 (es) 2012-05-07
CN1997371A (zh) 2007-07-11
WO2006014168A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
ATE537830T1 (de) Nicotinamid derivate und ihre verwendung als therapeutika
WO2007044085A3 (en) Heteroaryl compounds and their uses as therapeutic agents
ATE478044T1 (de) Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c
TW200626154A (en) Heterocyclic derivatives and their use as therapeutic agents
DE602006014367D1 (de) Multimere von pyrimidinonderivaten und deren verwendung als inhibitoren der humanen neutrophilelastase
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
ECSP066314A (es) Derivados piridilo y su uso como agentes terapéuticos
SE0401971D0 (sv) Piperidne derivatives
DE502004006507D1 (de) Imidazopyridazinon- und imidazopyridonderivate, deren herstellung und deren verwendung als arzneimittel
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
DE602005023015D1 (de) Indolderivate als viruzide
DE602005002562D1 (de) Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel
WO2007046868A3 (en) Thiazolidine derivatives and their uses as therapeutic agents
WO2005111002A3 (de) Substituierte cycloalkylderivate zur behandlung von atemswegerkrankungen
MXPA05012894A (es) Benzofuranos 3-sustituidos como agentes terapeuticos.
WO2007046867A3 (en) Piperidine derivatives and their uses as therapeutic agents
DK1483251T3 (da) C3-cyano-epothilon-derivater
ATE413392T1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE524181T1 (de) Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen
DE60321810D1 (de) Neue tricyclische derivate als ltd4 antagonisten
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents